Resistance to recombinant erythropoietin in a hemodialysis patient with heterozygous hemoglobinopathy J-Meinung

American Journal of Kidney Diseases

Volumn 29, Issue 5, 1997, Pages 769-772

  Tarng, Der Cherng ^a   Chang, Jan Gowth ^b   Huang, Tung Po ^b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NONE

Author keywords

erythropoietin resistance; hemodialysis; hemoglobin J Meinung; Hemoglobinopathy

Indexed keywords

HEMOGLOBIN VARIANT; RECOMBINANT ERYTHROPOIETIN;

ADULT; ANEMIA; ARTICLE; BILIRUBIN BLOOD LEVEL; CASE REPORT; CHRONIC KIDNEY FAILURE; CLINICAL FEATURE; DOSE RESPONSE; ERYTHROPOIESIS; HEMATOLOGICAL PARAMETERS; HEMODIALYSIS; HEMOGLOBINOPATHY; HUMAN; MALE; RETICULOCYTE COUNT; SPLENOMEGALY; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030986644     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0272-6386(97)90132-3     Document Type: Article

References (26)

1. Winearls CG, Oliver DO, Pippard MJ, Reid C, Downing MR, Cotes PM: Effect of human erythropoietin derived from recombinant DNA on the anemia of patients maintained by chronic hemodialysis. Lancet 2:1175-1178, 1986
2. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW: Correction of the anemia of end-stage renal disease with recombinant erythropoietin. Results of phase I and II clinical trial. N Engl J Med 316:73-78, 1987
3. Eschbach JW, Kelly MR, Haley NR, Abels RI, Adamson JW: Treatment of the anemia of progressive renal failure with recombinant human erythropoietin. N Engl J Med 321:158-163, 1989
4. Macdougall IC: Poor response to erythropoietin: Practical guidelines on investigation and management. Nephrol Dial Transplant 10:607-614, 1995
5. Van Wyck DB, Stivelman JC, Ruiz J, Kirlin LF, Katz MA, Ogden DA: Iron status in patients receiving erythropoietin for dialysis associated anemia. Kidney Int 35:712-716, 1989
6. Macdougall IC, Cavill I, Hulme B, Bain B, McGregor E, Mckay P, Sauders E, Coles GA, Williams JD: Detection of functional iron deficiency during erythropoietin treatment: A new approach. BMJ 304:225-226, 1992
7. Tarng DC, Chen TW, Huang TP: Iron metabolism indices for early prediction of the response and resistance to erythropoietin therapy in maintenance hemodialysis patients. Am J Nephrol 15:230-237, 1995
8. Bia MJ, Cooper K, Schnall S, Duffy T, Hendler E, Malluche J, Solomon L: Aluminium induced anemia: Pathogenesis and treatment in patients on chronic hemodialysis. Kidney Int 36:852-858, 1989
9. Rosenlöf K, Fyhrquist F, Tenhunen R: Erythropoietin, aluminium, and anaemia in patients on haemodialysis. Lancet 335:247-249, 1990
10. Rao DS, Shih MS, Mohini R: Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia. N Engl J Med 328:171-175, 1993
11. Muirhead N, Hodsman AB: Occult infection and resistance of anaemia to r-HuEPO therapy in renal failure. Nephrol Dial Transplant 5:232-234, 1990
12. Krantz SB: Pathogenesis and treatment of the anemia of chronic disease. Am J Med Sci 307:353-359, 1994
13. Ng YY, Chow MP, Lyou JY, Hu HY, Yung CH, Fan CD, Huang TP: Resistance to erythropoietin: Immunohemolytic anemia induced by residual formaldehyde in dialyzers. Am J Kidney Dis 21:213-216, 1993
14. Steinberg MH: Erythropoietin for anemia of renal failure in sickle cell disease. N Engl J Med 324:1369-1370, 1991
15. Roger SD, Macdougall IC, Thuraisingham RC, Raine AEG: Erythropoietin in anemia of renal failure in sickle cell disease. N Engl J Med 325:1175-1176, 1991
16. Tomson CRV, Edmunds ME, Chambers K, Bricknell S, Feehally J, Walls J: Effect of recombinant human erythropoietin on erythropoiesis in homozygous sickle-cell anaemia and renal failure. Nephrol Dial Transplant 7:817-821, 1992
17. Lai KN, Wong KC, Li PKT, Lui SE: Use of recombinant erythropoietin in thalassemic patients on dialysis. Am J Kidney Dis 14:239-245, 1992
18. Cozma G, Cozma MC, Mattes U: Beneficial effect of recombinant human erythropoietin in beta thalassemia patients on dialysis. Nephrol Dial Transplant 7:82-83, 1992
19. Winearls CG, Hughes RT, Pippard MJ, Cotes PM: Erythropoietin dose requirement in a patient with HbH disease and renal failure. Nephrol Dial Transplant 7:1052-1054, 1992
20. Cheng IKT, Lu HB, Wei DCC, Cheng SW, Chan CY, Lee FCP: Influence of thalassemia on the response to recombinant human erythropoietin in dialysis patients. Am J Nephrol 13:142-148, 1993
21. Kagan A, Sinay-Trieman L, Bar-Khayim Y: Recombinant human erythropoietin for anaemia in thalassemic minor patients on dialysis. Nephrol Dial Transplant 10:2375-2376, 1995
22. Liu TC, Yen JS, Shen JS, Chen YH, Lee LS, Chen PH, Chang JG: Rapid molecular diagnosis of hemoglobin variants by RT-PCR of reticulocyte mRNA and direct sequencing. Hemoglobin 16:379-388, 1992
23. Chang JG, Chen PH, Chiou SS, Lee LS, Perng LI, Liu TC: Rapid diagnosis of β-thalassemia mutations in Chinese by naturally and amplified created restriction sites. Blood 80:2092-2096, 1992
24. Bommer J, Barth H-P, Zeier M, Mandelbaum A, Bommer G, Ritz E, Reichel H, Novack R: Efficacy comparison of intravenous and subcutaneous recombinant human erythropoietin administration in hemodialysis patients. Contrib Nephrol 88:136-143, 1991
25. Drüeke TB: R-HuEPO hyporesponsiveness - Who and why? Nephrol Dial Transplant 10:62-68, 1995 (suppl 2)
26. Erslev AJ: The therapeutic role of recombinant erythropoietin in anaemic patients with intact endogenous production of erythropoietin. Semin Oncol 19:14-18, 1992 (suppl 8)